RESTON, VA – Wellisen Nutraceuticals is producing the ZIVO algae strain exclusively for ZIVO under a license agreement. ZIVO is a Michigan-based biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary strains.
Wellisen is an India-based algae producer with a history of more than 20 years of robust research and development. Wellisen sets the standard to advance health and wellness across the globe. Wellisen’s spirulina is made for use in dietary supplements and food ingredients, for aquaculture and animal feeds. Phycocyanin, a derivative of spirulina, is used as a natural coloring agent in foods, pharmaceuticals and cosmetics, offering an algae-based, blue-dye alternative which brands around the world can trust.
Under a licensing agreement with ZIVO, Wellisen is working to commercially scale up the production of Zivo strain. “We are pleased to partner with ZIVO Bioscience as it works to scale up production throughout Asia for its stated purpose, and our shared vision, of developing natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in human and animals,” Sanjay Puri, President of Wellisen Nutraceuticals said. “ZIVO has filed patents for their strain. Wellisen fully supports these efforts to bring about sustainable health and nutrition across the spectrum.”
Wellisen is an India-based nutraceuticals company committed to advancing health and wellness across the globe. With innovative algae production and one of the best R&D teams in the business, Wellisen is a global leader in sustainable health and nutrition. Wellisen is located in Mysuru, India with headquarters in Reston, Virginia, USA.